FDAorphan designation65% confidence
Medical Products for Rare Diseases and Conditions
Source: FDA
Why This Matters
Why this matters: provides agency context on orphan designation that may shape timing or evidence expectations for nontuberculous mycobacterial lung disease patients.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Pulmonology · Nontuberculous Mycobacterial Lung Disease
- Sub-indication
- General
Related signal: Inhaled 3% hypertonic saline shows promise for antibiotic-naïve NTM lung disease